Feedback / Questions
Zejula (niraparib) - GSK, ZAI Lab, J&J, Takeda
dostarlimab (TSR-042) - GSK
Zejula + dostarlimab: Regulatory submission for 2L+ ovarian cancer (based on MOONSTONE trial) in H2 2021
(GSK)
-
Apr 30, 2020 -
Q1 2020 Results
Regulatory
•
Oncology • Ovarian Cancer
https://www.gsk.com/media/5957/q1-2020-results-slides.pdf
Apr 30, 2020
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious